Kokoram a ɛwɔ ahoɔmmerɛ mu yɛ kokoram a ɛtɔ so mmienu a ɛtaa yɛ mmarima wɔ wiase nyinaa, a wɔkyekyɛ mu a nnipa ɔpepem 1.276 na wɔnyaa bi wɔ 2018 mu, a ɛkyerɛ sɛ kokoram a ɛwɔ mmarima mu no mu ɔha mu nkyɛm 7.1 na wɔnyaa bi.
Owu ho nsunsuanso ma kokoram yɛ hu nso, na wobu akontaa sɛ nnipa 37,005 na wowuwui wɔ wiase nyinaa wɔ afe 2018 mu.
Nanso, owuo no gu ahorow wɔ mmeaɛ bebree mu, a Afrika Atɔeɛ fam no, wɔn a wɔwɔ yareɛ yi ho nsunsuansoɔ a ɛboro so wɔ wiase nyinaa no wɔ beaɛ a ɛtɔ so enum, na Nigeria nso wɔ nnipa ne sikasɛm mu nsunsuansoɔ a ɛboro so wɔ saa mantam yi mu.
Wɔ Nigeria no, kokoram a ɛwɔ obi dɛmdibea yɛ kokoram a ɛtaa di mmarima nya na ekum wɔn paa, na wobu akontaa sɛ, kokoram no ka mmarima 100,000 biara a, emu 32.8 na ekum wɔn, na 16.3 na ekum wɔn.
Eyi boro nnipa a wowu wɔ Amerika Atifi fam no mmɔho.
Akwan a wɔfa so hu yare no ntɛm, nneɛma kakraa bi a wɔde hwehwɛ mu hu yare no, ne sɛnea wɔkora yare no ho nsɛm so na wɔde bɔ ho amanneɛ no ka ho bi na nnipa pii wu wɔ Nigeria.
Wɔ United States no, kokoram a ɛwɔ obi dɛmdi mu yɛ ade a ɛtɔ so mmienu a ekunkum nnipa wɔ kokoram mu, na mmarima bɛyɛ 40,000 na ekunkum wɔn afe biara.
Mframa mu kokoram a ekunkum nnipa no so atew nkakrankakra fi afe 1990 mu, nanso ɛda so yɛ yare a ɛhaw nnipa pii.
Ne nyinaa mu no, kokoram yɛ yareɛ a ekum nnipa, titiriw wɔ mmeae a wɔnnya ayaresa ne nneɛma pii a wɔde hwehwɛ mu.
Nanso, sɛ wohu no ntɛm na wɔsa no yare a, ebetumi ama yare no so atew na ama nnipa a wowuwu no so atew.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Abɔdin: ayaresa']
['Wɔayɛ wɛbsaet yi sɛ wɔmfa nkyerɛkyerɛ na wɔnka ho asɛm kɛkɛ, na ɛnyɛ sɛ wɔde ayaresa ho afotu anaa adwumakuw bi mmoa rema.']
['Ɛnsɛ sɛ wɔde nsɛm a wɔde ama no di dwuma de hwehwɛ yare anaa yare bi ho ayaresa, na ɛsɛ sɛ wɔn a wɔrehwehwɛ ayaresa ho afotu no ne oduruyɛfo a ɔwɔ tumi krataa di nkitaho.']
['Yɛsrɛ wo hyɛ no nsow sɛ amemene no mu mfiri a ɛma nsɛmmisa ho mmuae no nyɛ pɛpɛɛpɛ bere a ɛfa akontaahyɛde ho no. Sɛ nhwɛso no, nnipa dodow a wɔanya yare pɔtee bi.']
["Hwehwɛ afotu fi wo dɔkota anaa ayaresafo a wɔfata hɔ bere biara wɔ yareɛ ho. Nnyae ayaresa ho afotuo a wɔn a wɔn ho akokwaw de ma no ho adwenemu anaa twentwɛn wo nan ase sɛ worebɛhwehwɛ esiane biribi a woakenkan wɔ wɛbsaet yi so nti. Sɛ ɛyɛ wo sɛ wowɔ yareɛ ho nsɛmmisa a, frɛ 911 anaa kɔ ayaresabea a ɛbɛn wo pɛɛ ntɛm ara. Saa wɛbsaet yi anaa dwuma a wode di no mma wonnya oduruyɛfo ne ɔyarefo ayɔnkofa biara. BioMedLib anaa n'adwumayɛfoɔ anaa obiara a ɔde ne ho bɔ wɛbsaet yi ho dawuro biara nni mu, a ɛkyerɛ anaa enni mu, fa nsɛm a wɔde ama wɔ ha anaa dwuma a wɔde di no ho."]
['Disclaimer: copyright']
["Digital Millennium Copyright Act a w'atwe no afe 1998 wɔ U.S. Mmara 17 § 512 (DMCA) no ma wɔn a w'wɔ tumi sɛ wɔtwe wɔn ho fi nneɛma a wɔde agu intanɛt so ho kwan."]
['Sɛ wogye di sɛ wo nsɛm anaa nneɛma bi a ɛwɔ yɛn wɛbsaet anaa yɛn dwumadie mu no to wo mmara a woahyehyɛ no so a, wo (anaa wo dwumadifoɔ) bɛtumi de nkaebɔ ama yɛn de apɛ sɛ yɛyi nsɛm anaa nneɛma no firi hɔ anaa yɛsi ho kwan.']
["Ɛsɛ sɛ wɔde nkaebɔ fa e-mail so kɔma wɔn (hwɛ 'Contact' section ma e-mail address)."]
['DMCA hwehwɛ sɛ wo dawurubɔ a ɛfa mmara a obi abu so ho no de nsɛm a edidi so yi ka ho: (1) nkyerɛwde a ɛkyerɛ adwuma a mmara bɔ ho ban a obi abu so no; (2) nsɛm a wɔkyerɛ sɛ obi abu so no ne ɛho nsɛm a ɛfata a ɛbɛma yɛahunu faako a saa nsɛm no wɔ; (3) wo nkitahodi ho nsɛm, a wo address, fon number ne email ka ho; (4) krataa a woakyerɛ sɛ wowɔ gyidie pa sɛ nea woabɔ ho dawuru no nni mmara no wura anaa nea ɔhwɛ so anaa mmara biara tumi mu.']
['(5) sɛ wo de wo nsa ahyɛ krataa ase, na wohyɛ sɛ wobedi atoro, sɛ nsɛm a ɛwɔ krataa no mu yɛ nokware, na wowɔ tumi sɛ wode wo nsa bɛka nneɛma a obi akyerɛw abrɛ wo ase no;']
["و (6) physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner's behalf."]
['Sɛ woantwerɛ nsɛm a ɛwɔ soro yi nyinaa amfiri wo nkrataa no mu a, ɛbɛtumi ama wo kyɛfa no akyɛ.']
['Nkitahodi']
['Yɛsrɛ wo, fa nsɛmmisa anaa nyansahyɛ biara fa e-mail so brɛ yɛn.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɛfa ho']
['BioMedLib de kɔmputa a ɛyɛ adwuma ankasa (fidie a wɔde sua ade) na ɛyɛ nsɛmmisa ne mmuae.']
['Yɛde yɛn afi ayaresa ho nhoma ɔpepem 35 a ɛwɔ PubMed/Medline ase. Afei nso, RefinedWeb wɛb nkratafa.']
